Loading
LAE118 is an experimental pill from Laekna Therapeutics, in phase 1 trials for advanced solid tumours.
LAE118 is a small molecule from Laekna Therapeutics. An allosteric PI3K-alpha inhibitor designed to act on the mutant forms of the enzyme (company poster title). The phase 1 study NCT07787520 tests it alone and with fulvestrant and palbociclib; the company says the first subject was enrolled in August 2026. Rights outside China were licensed to Vasque Bio in June 2026. Whether it works in people has not been established.
An allosteric PI3K-alpha inhibitor designed to act on the mutant forms of the enzyme (company poster title). Connects to PIK3CA / PI3K-alpha.
1.LAE118 slips into a pocket on PIK3CA / PI3K-alpha.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LAE118" OR ABSTRACT:"LAE118") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LAE118, not a curated reading list.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares PIK3CA / PI3K-alpha and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/